Total submissions: 20
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
LDLR- |
RCV000237459 | SCV000295458 | likely pathogenic | Familial hypercholesterolemia 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
Cardiovascular Research Group, |
RCV000237459 | SCV000322957 | uncertain significance | Familial hypercholesterolemia 1 | 2016-03-01 | criteria provided, single submitter | research | 0/184 non-FH alleles; 0/100 healthy control individuals |
Centre de Génétique Moléculaire et Chromosomique, |
RCV000237459 | SCV000503353 | likely pathogenic | Familial hypercholesterolemia 1 | 2016-12-16 | criteria provided, single submitter | clinical testing | subjects mutated among 2600 FH index cases screened = 10 , family members = 5 with unclear co-segregation / previously described in association with FH/Software predictions: Conflicting |
Molecular Genetics Laboratory, |
RCV000237459 | SCV000540820 | likely pathogenic | Familial hypercholesterolemia 1 | 2016-11-05 | criteria provided, single submitter | clinical testing | |
U4M - |
RCV000237459 | SCV000583835 | pathogenic | Familial hypercholesterolemia 1 | 2017-03-30 | criteria provided, single submitter | clinical testing | |
Laboratory of Genetics and Molecular Cardiology, |
RCV000237459 | SCV000588582 | uncertain significance | Familial hypercholesterolemia 1 | 2016-03-01 | criteria provided, single submitter | research | |
Fundacion Hipercolesterolemia Familiar | RCV000237459 | SCV000607602 | uncertain significance | Familial hypercholesterolemia 1 | 2016-03-01 | criteria provided, single submitter | research | |
Integrated Genetics/Laboratory Corporation of America | RCV000590270 | SCV000697197 | pathogenic | Familial hypercholesterolemia | 2017-06-05 | criteria provided, single submitter | clinical testing | Variant summary: The LDLR c.1474G>A (p.Asp492Asn) variant involves the alteration of a conserved nucleotide. 4/5 in silico tools predict a damaging outcome for this variant. This variant was found in 2/121480 control chromosomes at a frequency of 0.0000165, which does not exceed the estimated maximal expected allele frequency of a pathogenic LDLR variant (0.0012508). This variant has been reported in multiple affected FH patients including heterozygous patients and compound heterozygous patients (Mak_1998, Chiou_2010, Bertolini_2013, Blaha_2015). Variant was shown to segregate with disease in at least one of the reported families (Blaha_2015). Variants involving nearby nucleotides such as c.1474G>C, c.1474delG, c.1475A>G, etc, have been reported in affected individuals suggesting variant of interest is located in a mutiaotn hotspot. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic. Taken together, this variant is classified as pathogenic. |
Robarts Research Institute, |
RCV000237459 | SCV000782916 | uncertain significance | Familial hypercholesterolemia 1 | 2018-01-02 | criteria provided, single submitter | clinical testing | |
Human Genome Sequencing Center Clinical Lab, |
RCV000237459 | SCV000839982 | likely pathogenic | Familial hypercholesterolemia 1 | 2017-04-26 | criteria provided, single submitter | clinical testing | This c.1474G>A (p.Asp492Asn) variant has been reported in a 42 year old male patient with familial hypercholesterolemia from a cohort of 30 patients [reported as D471N, FH Graz-1 in PMID 9763532]. This variant was also reported in a patient presenting with a total cholesterol level of 23 mmol/L and xanthomas [PMID 25936317]; this patient also carried a second allele (p.Gly592Glu), which is classified as pathogenic by our laboratory . This variant was further detected in a patient from a cohort of 2,078 patients from Italy [PMID 23375686]; this patient also carried a p.Cys698Trp variant, classified as a variant of unknown significance by our laboratory at this time. Additional variants affecting the same amino acid at position 492 (p.Asp492Gly and p.Asp492His) have been reported in patients with familial hypercholesterolemia [PMID 16250003, 10208479].This variant was reported in 2 heterozygous individuals in the ExAC database (http://exac.broadinstitute.org/variant/19-11224326-G-A). Asparagine at amino acid position 492 of the LDLR protein is highly conserved in mammals. While not validated for clinical use, the computer-based algorithms predict this p.Asp492Asn change to be deleterious. This variant is thus classified as likely pathogenic. |
Color Health, |
RCV000590270 | SCV000903572 | likely pathogenic | Familial hypercholesterolemia | 2019-12-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000590270 | SCV000939301 | pathogenic | Familial hypercholesterolemia | 2019-11-11 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with asparagine at codon 492 of the LDLR protein (p.Asp492Asn). The aspartic acid residue is highly conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is present in population databases (rs373646964, ExAC 0.003%). This variant has been observed to segregate with familial hypercholesterolemia in a family (PMID: 10230472). This variant has also been observed in several individuals with myocardial infarction (PMID: 25647241, 25487149) and many individuals with familial hypercholesterolemia (PMID: 9763532, 25936317, 20236128, 11005141, 23375686, 27680772, 22698793). This variant is also known as Asp471Asn and Graz-1. ClinVar contains an entry for this variant (Variation ID: 161285). A single experimental study showed that this missense change did not disrupt LDL uptake, but this has not been confirmed in additional studies (PMID: 25647241). This variant disrupts the p.Asp492 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been observed in individuals with LDLR-related disease (PMID: 16250003, 10208479), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Hudson |
RCV000237459 | SCV001423554 | pathogenic | Familial hypercholesterolemia 1 | 2020-03-10 | criteria provided, single submitter | research | |
Institute of Human Genetics, |
RCV000237459 | SCV001428819 | uncertain significance | Familial hypercholesterolemia 1 | 2019-03-20 | criteria provided, single submitter | clinical testing | |
Brunham Lab, |
RCV000237459 | SCV001432652 | likely pathogenic | Familial hypercholesterolemia 1 | 2018-12-06 | criteria provided, single submitter | research | |
Laboratory of Molecular Genetics, |
RCV000590270 | SCV001482455 | uncertain significance | Familial hypercholesterolemia | criteria provided, single submitter | research | ||
Dept. |
RCV000161989 | SCV000189564 | not provided | not provided | no assertion provided | in vitro | ||
CSER _CC_NCGL, |
RCV000148592 | SCV000190307 | uncertain significance | Hypercholesterolaemia | 2014-06-01 | no assertion criteria provided | research | |
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, |
RCV000237459 | SCV000606438 | pathogenic | Familial hypercholesterolemia 1 | no assertion criteria provided | research | ||
Broad Institute Rare Disease Group, |
RCV000237459 | SCV001423102 | pathogenic | Familial hypercholesterolemia 1 | 2020-01-22 | no assertion criteria provided | curation | The p.Asp492Asn (p.Asp471Asn) variant in LDLR has been reported in at least 30 individuals (including 13 Italian, 3 Chinese, 2 Norwegian, 2 Taiwanese, 1 Czech, and 1 Saudi Arabian individuals) with Familial Hypercholesterolemia, segregated with disease in up to 14 affected relatives from up to 7 families (PMID: 25647241, 26748104, 29172679, 11737238, 17094996, 23375686, 11005141, 25936317, 15199436, 17539906, 20538126, 9763532, 21310417, 12436241, 19446849; DOI: 10.2217/clp.14.6), and has been identified in 0.01087% (2/18394) of East Asian chromosomes and 0.003518% (4/113704) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs373646964). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The phenotype of a homozygous individual with this variant is highly specific for Familial Hypercholesterolemia based on xanthomas and family history consistent with disease (DOI: 10.2217/clp.14.6). In summary, this variant meets criteria to be classified as pathogenic for Familial Hypercholesterolemia in an autosomal dominant manner based on multiple reports in individuals with Familial Hypercholesterolemia and cosegregation with disease. ACMG/AMP Criteria applied: PS4, PP1_Moderate, PP3, PP4 (Richards 2015). |